AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T18:36:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Fri 14 Mar 25, 12:35 PMLife Sciences Investor Forum Agenda Announced for March 13th
Wed 12 Mar 25, 05:12 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.83100M | -17.50400M | -17.98400M | -38.83700M | -14.18500M |
| Minority interest | - | - | - | - | - |
| Net income | -8.83100M | -17.50400M | -17.98400M | -38.84500M | -14.18900M |
| Selling general administrative | 3.96M | 5.34M | 5.99M | 5.75M | 5.43M |
| Selling and marketing expenses | - | - | 7.37M | - | - |
| Gross profit | -0.37600M | -12.53700M | -15.16900M | -0.24160M | -0.23950M |
| Reconciled depreciation | 0.38M | 0.45M | 0.41M | 0.39M | 0.38M |
| Ebit | -9.01900M | -17.87800M | -21.15900M | -38.82900M | -14.22100M |
| Ebitda | -8.64300M | -17.75200M | -20.97000M | -17.74900M | -14.03100M |
| Depreciation and amortization | 0.38M | 0.13M | 0.19M | 21.08M | 0.19M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -9.01900M | -17.87800M | -18.55900M | -38.82900M | -14.22100M |
| Other operating expenses | 9.02M | 17.88M | 18.56M | 18.14M | 14.22M |
| Interest expense | - | - | - | 0.00200M | 0.00400M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | 0.13M | 0.54M | 0.46M | -0.00200M | -0.00400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -17.50400M | -0.00000M | 0.00800M | 0.00400M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 5.43M |
| Total operating expenses | 8.64M | 5.34M | 3.39M | 18.14M | 14.22M |
| Cost of revenue | 0.38M | 12.54M | 15.17M | 0.24M | 0.24M |
| Total other income expense net | 0.19M | 0.37M | 0.57M | -0.00800M | 0.04M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -8.83100M | -17.50400M | -18.02100M | -38.83700M | -14.18500M |
| Net income applicable to common shares | - | - | - | -38.83700M | -14.18500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 9.71M | 13.46M | 31.26M | 40.84M | 79.39M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.40M | 0.51M | 1.77M | 2.24M | 0.57M |
| Total liab | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M |
| Total stockholder equity | 6.33M | 9.52M | 26.38M | 39.57M | 77.55M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.99M | 0.23M | 1.80M | 0.36M | 0.01M |
| Common stock | 0.01M | 0.01000M | 0.01000M | 0.00800M | 0.10M |
| Capital stock | 0.01M | 0.01000M | 0.01000M | 0.00800M | 0.10M |
| Retained earnings | -342.24900M | -333.41800M | -315.91400M | -297.93000M | -259.09300M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | 0.00000M | 19.09M |
| Other assets | - | - | 0.00000M | 0.05M | 0.05M |
| Cash | 7.03M | 9.86M | 26.43M | 37.14M | 58.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.21M | 2.43M | 3.26M | 1.22M | 1.54M |
| Current deferred revenue | - | - | - | - | 0.72M |
| Net debt | -5.52000M | -8.05400M | -24.57500M | -36.84700M | -58.17100M |
| Short term debt | 0.33M | 0.60M | 0.24M | 0.24M | 0.24M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.50M | 1.81M | 1.85M | 0.30M | 0.53M |
| Other stockholder equity | 348.57M | 342.93M | 342.29M | 337.49M | 336.54M |
| Property plant equipment | - | - | - | 0.62M | 0.93M |
| Total current assets | 8.13M | 11.58M | 29.09M | 40.18M | 59.32M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 39.57M | 58.46M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.71M | 1.22M | 0.89M | 0.72M | 0.00000M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | 0.07M | - |
| Accounts payable | 0.89M | 1.54M | 1.22M | 0.61M | 0.58M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.10M | 0.03M | 0.05M | 0.05M | 0.05M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.58M | 1.88M | 2.17M | 0.66M | 20.07M |
| Capital lease obligations | 1.50M | 1.81M | 1.85M | 0.30M | 0.53M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.00800M | -0.07100M | -0.07400M | -0.05200M |
| Change to liabilities | - | - | - | -1.03700M | 0.22M |
| Total cashflows from investing activities | -0.01200M | -0.00800M | -0.11800M | -0.07400M | -0.05200M |
| Net borrowings | - | 0.00000M | -0.00700M | -0.02700M | -0.03900M |
| Total cash from financing activities | 5.37M | 0.00000M | 3.99M | -0.02700M | 38.47M |
| Change to operating activities | - | - | - | -1.67500M | -0.16900M |
| Net income | -8.83100M | -17.50400M | -17.98400M | -38.83700M | -14.18500M |
| Change in cash | -2.83500M | -16.49300M | -10.79100M | -21.53600M | 25.70M |
| Begin period cash flow | 9.94M | 26.43M | 37.22M | 58.76M | 33.06M |
| End period cash flow | 7.10M | 9.94M | 26.43M | 37.22M | 58.76M |
| Total cash from operating activities | -8.19200M | -16.48500M | -14.66600M | -21.43500M | -12.71900M |
| Issuance of capital stock | 5.37M | 0.00000M | 4.00M | 0.00000M | 38.51M |
| Depreciation | 0.07M | 0.13M | -1.38800M | 0.39M | 0.19M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.51M | -0.32500M | -0.17400M | 0.00000M | 0.56M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 5.37M | - | 0.00000M | -0.07400M | -0.05200M |
| Change to netincome | - | - | - | 19.73M | 0.48M |
| Capital expenditures | 0.01M | 0.00800M | 0.12M | 0.07M | 0.05M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.29M | 0.14M | 2.34M | -2.71200M | 0.80M |
| Stock based compensation | 0.27M | 0.64M | 0.80M | 0.85M | 0.72M |
| Other non cash items | 0.00300M | 0.11M | 1.56M | 18.87M | -0.19500M |
| Free cash flow | -8.20400M | -16.49300M | -14.78400M | -21.50900M | -12.77100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COCP Cocrystal Pharma Inc |
0.06 6.00% | 1.06 | - | - | 92.45 | 3.15 | 0.71 | 0.66 |
| NVO Novo Nordisk A/S |
1.54 3.36% | 47.42 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.63 0.35% | 468.42 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
5.53 0.90% | 618.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
19805 North Creek Parkway, Bothell, WA, United States, 98011
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Dr. Sam Lee Ph.D. | Co-Founder, Interim Co-CEO & Pres | 1960 |
| Mr. James J. Martin CPA, CPA, M.B.A., MBA | Interim Co-CEO, CFO & Corp. Sec. | 1967 |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-CEO & President | 1960 |
| Mr. James J. Martin CPA, M.B.A. | Co-CEO, CFO & Corporate Secretary | 1967 |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
| Prof. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...